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Is the interaction between ticlopidine
and cyclosporin dose related? Report
of three cases
T
iclopidine is an effective anti-platelet agent used
for prevention of thrombosis (13). It was re-
ported that treatment with ticlopidine at the dose
of 250 mg daily in kidney transplant patients caused
significant reduction of cyclosporin A (CsA) blood levels
(4, 5). In heart transplant patients treated with higher
doses of ticlopidine 500 mg daily, it was found to cause
significant decrease of cyclosporin concentration but not
in those treated with only 250 mg daily (1, 2). It was
thought that ticlopidine interacts with cyclosporin meta-
bolism at cytochrome P450 (13).
We report three living kidney donor recipients whose
blood level of cyclosporin decreased significantly under
treatment with a very low dose of ticlopidine of 100 mg
daily.
The patients were on immunosuppressive treatment
with steroids, CsA, and mycophenolate mofetil (MMF)
or azathioprin. The total daily CsA dose was 125150
mg. The patients developed severe hypertension 15 days
to 4 months after kidney transplantation. Serum creati-
nine was normal except in patient number 2 (Table 1).
Doppler ultrasonography confirmed significant stenosis
of at least 70% degree in the artery of the transplanted
kidney. Percutanuous transluminal angioplasty (PTA)
with stent placement was performed. Anti-platelet treat-
ment with aspirin (160 mg/day) and ticlopidine (100 mg/
day) were given to prevent thrombosis. CsA blood levels
were monitored by C0 (before morning dose) (Fig. 1).
Under ticlopidine treatment, CsA blood levels decreased
in patient 1 from 137 to 112 ng/ml, in patient 2 it
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Table 1. Characteristic of three patients with kidney transplantation and renal artery stenosis
Characteristics Patient 1 Patient 2 Patient 3
Age (years) 18 26 20
Gender F M F
HLA mismatch 3 3 3
Serum creatinine (mg/l) 8.5 15.4 7.1
Number of anti-hypertensive
drugs
34 3
Diagnosis of stenosis after
transplantation
2 months 15 days 4 months
Date of PTA 2 months after the diagnosis 14 months after diagnosis 2 months after the diagnosis
Note: PTA, percutanuous transluminal angioplasty.
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Day 0: Start of ticlopidine therapy.  
Day 0: Initiation of ticlopidin therapy.
Fig. 1. Cyclosporin A blood levels (C0) and doses during 60 days of ticlopidine therapy: follow of blood CsA levels and doses in
the three patients.
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decreased from 131 to 106 ng/ml. Consequently CsA dose
had been increased by 5075 mg/day. No signs of acute
kidney transplant rejection were observed.
In summary: In kidney transplant patients, ticlopidine
can cause a significant decrease in CsA blood level even
at a low dose of ticlopidine. The interaction of ticlopidine
with CsA seems to be not related to the doses. We
recommend careful monitoring of CsA blood level in
patients treated with ticlopidine.
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